Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
InnoCom Bio Equities, Inc. is a venture capital firm based in San Francisco, California, established to provide investment opportunities in innovative life sciences technologies. Founded with a clear mission, the firm focuses on early-stage pharmaceutical and therapeutic companies, particularly those with FDA Phase I and II clinical-stage assets. This strategic focus allows InnoCom to bridge the gap from pre-clinical work to partnerships with larger pharmaceutical companies at Phase III.
Currently, InnoCom Bio Equities manages a fund size of $250 million and has invested approximately $165 million across its portfolio of 13 companies. The firm aims to expedite value creation through a diversified portfolio, targeting exclusive intellectual property opportunities that can lead to royalties and out-licensing. Recognized for its expertise in the life sciences sector, InnoCom has garnered accolades, including the title of
The firm invests in early-stage life sciences technologies, providing seed capital to innovators and founders. InnoCom Bio Equities emphasizes exclusive intellectual property opportunities, aiming for royalties and out-licensing as part of its diversified investment strategy.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.